Shingles vaccine safety study for transplant recipients
Part of Immune system & allergy clinical trials.
This trial tests whether the shingles vaccine (RZV) is safe and works well for organ transplant recipients and their household members. It also includes people on dialysis or certain immunosuppressants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (50 or older if you live with a transplant recipient).
- You have had chickenpox before or have antibodies from a past infection.
- You are an organ transplant recipient on specific medications, or you live with a transplant recipient, or you are on a single immunosuppressant called rapamycin, or you are on dialysis.
- You are not allergic to any ingredient in the shingles vaccine.
- You are not currently pregnant.
- You do not have a primary immune deficiency or a known poor response to vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the shingles vaccine in young adults who have had a solid organ transplant (like a kidney or liver) more than a year ago. The goal is to see if the vaccine works well and is safe for people on stable anti-rejection medicines.
This study tests whether an extra dose of the Shingrix shingles vaccine can boost protection in people who have had a solid-organ transplant. If you already received both doses of Shingrix after your transplant, this trial will give you an additional dose to see if it further strengthens your immune response.
This study tests whether an investigational shingles (herpes zoster) vaccine is safe and helps prevent shingles in children who have had a kidney transplant. Because these children take medicines to prevent rejection, the study specifically looks at vaccine effects in this higher-risk group.
This Phase 3 study tests whether the shingles vaccine Shingrix is safe and effective for adults with chronic kidney failure who are on the transplant waiting list. It aims to protect you from shingles while you may be dealing with transplant-related immune changes.
This Phase 2 study tests whether an additional Shingrix (RZV) vaccine dose helps prevent shingles in people who previously had an allogeneic bone marrow or stem cell transplant. It focuses on people who are at least a year out from their first two Shingrix doses.
This Phase 2 study looks at how well the shingles vaccine works in people who had an allogeneic (donor) stem cell transplant. It aims to measure the body’s immune response to the vaccine and check that it’s safe in this recovery period.
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.